Vobarilizumab, binding interleukin‐6 receptor (IL‐6R), was developed by Ablynx for the treatment of autoimmune diseases and confirmed its low immunogenicity through clinical trials.22 The gene discussed is IL6R; the disease is autoimmune disease.